Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 51654W101 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Empery Asset Management, LP
13G
|
10.0% |
8/4/2026
Event 6/30/2026
|
|
| Empery Asset Management, LP | 10.0% | ||
| Ryan M. Lane | 10.0% | ||
| Thomas A. Satterfield, Jr. 13G/A Amendment 1 | 7.6% |
7/23/2026
Event 6/30/2026
|
|
|
Bios Equity Partners, LP
13D/A
Amendment 7
|
4.5% |
5/15/2026
Event 5/15/2026
|
|
| Bios Advisors GP, LLC | 4.5% | ||
| Aaron G.L. Fletcher | 4.5% | ||
| Cavu Management, LP | 4.5% | ||
| Cavu Advisors, LLC | 4.5% | ||
| Leslie W. Kreis | 4.5% | ||
| Bios Equity Partners, LP | 2.1% | ||
| Bios Equity Partners II, LP | 2.4% | ||
| Bios Capital Management, LP | 4.5% | ||
| Bios Fund II NT, LP | 0.2% | ||
| Bios Fund II QP, LP | 1.7% | ||
| Bios Fund II, LP | 0.5% | ||
| BP Directors, LP | 0.2% | ||
| Bios Fund I QP, LP | 0.7% | ||
| Bios Fund I, LP | 1.2% | ||
|
Bios Equity Partners, LP
13D/A
Amendment 6
|
7.4% |
4/16/2026
Event 4/16/2026
|
|
| Bios Equity Partners, LP | 3.7% | ||
| Fletcher Aaron G.L. | 7.4% | ||
| BIOS Advisors GP, LLC | 7.4% | ||
| BIOS Capital Management, LP | 7.4% | ||
| Bios Equity Partners II, LP | 3.7% | ||
| BIOS Fund II, LP | 0.8% | ||
| BIOS Fund II NT, LP | 0.3% | ||
| BIOS Fund II QP, LP | 2.6% | ||
| BIOS Fund I, LP | 2.2% | ||
| BIOS Fund I QP, LP | 1.3% | ||
| BP Directors, LP | 0.2% | ||
| Cavu Advisors, LLC | 7.4% | ||
| Cavu Management, LP | 7.4% | ||
| Kreis Leslie W. | 7.4% | ||
| Thomas A. Satterfield, Jr. 13G | 5.1% |
4/3/2026
Event 3/30/2026
|
|
|
Bios Equity Partners, LP
13D/A
Amendment 5
|
8.6% |
2/23/2026
Event 2/20/2026
|
|
| Bios Fund I, LP | 2.6% | ||
| Bios Equity Partners II, LP | 4.3% | ||
| Bios Fund I QP, LP | 1.5% | ||
| Bios Fund II, LP | 0.9% | ||
| Bios Fund II QP, LP | 3.0% | ||
| Bios Fund II NT, LP | 0.4% | ||
| BP Directors, LP | 0.2% | ||
| Bios Equity Partners, LP | 4.3% | ||
| Bios Capital Management, LP | 8.6% | ||
| Bios Advisors GP, LLC | 8.6% | ||
| Cavu Management, LP | 8.6% | ||
| Cavu Advisors, LLC | 8.6% | ||
| Leslie W. Kreis | 8.6% | ||
| Aaron G.L. Fletcher | 8.6% | ||
|
Bios Equity Partners, LP
13D/A
Amendment 4
|
10.0% |
6/13/2025
Event 6/12/2025
|
|
| Bios Fund I, LP | 3.0% | ||
| Bios Fund I QP, LP | 1.8% | ||
| Bios Fund II, LP | 1.1% | ||
| Bios Fund II QP, LP | 3.5% | ||
| Bios Fund II NT, LP | 0.5% | ||
| BP Directors, LP | 0.2% | ||
| Bios Equity Partners, LP | 4.99% | ||
| Bios Equity Partners II, LP | 4.98% | ||
| Cavu Management, LP | 10.0% | ||
| Bios Capital Management, LP | 10.0% | ||
| Cavu Advisors, LLC | 10.0% | ||
| Bios Advisors GP, LLC | 10.0% | ||
| Leslie W. Kreis | 10.0% | ||
| Aaron G.L. Fletcher | 10.0% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 1 | 8.50 k | $8.59 k |
| 2026 Q2 | 39 | 2.88 M | $12.0 M |
| 2026 Q1 | 33 | 2.10 M | $2.87 M |
| 2025 Q4 | 35 | 2.28 M | $6.91 M |
| 2025 Q3 | 32 | 2.28 M | $9.93 M |
| 2025 Q2 | 37 | 2.25 M | $7.11 M |
| 2025 Q1 | 35 | 2.43 M | $8.62 M |
| 2024 Q4 | 35 | 2.50 M | $8.00 M |
| 2024 Q3 | 34 | 1.34 M | $4.90 M |
| 2024 Q2 | 43 | 1.29 M | $6.01 M |
| 2024 Q1 | 41 | 1.11 M | $9.77 M |
| 2023 Q4 | 35 | 1.16 M | $4.95 M |
| 2023 Q3 | 30 | 1.15 M | $3.93 M |
| 2023 Q2 | 28 | 1.15 M | $6.50 M |
| 2023 Q1 | 24 | 1.08 M | $5.23 M |
| 2022 Q4 | 27 | 1.09 M | $5.56 M |
| 2022 Q3 | 30 | 1.44 M | $6.84 M |
| 2022 Q2 | 27 | 1.42 M | $8.06 M |
| 2022 Q1 | 26 | 1.45 M | $10.4 M |
| 2021 Q4 | 37 | 1.67 M | $13.2 M |
| 2021 Q3 | 26 | 1.40 M | $15.7 M |
| 2021 Q2 | 23 | 1.35 M | $19.7 M |
| 2021 Q1 | 26 | 1.40 M | $25.5 M |
| 2020 Q4 | 11 | 83.0 k | $1.60 M |
| 2020 Q3 | 13 | 160 k | $3.02 M |
| 2020 Q2 | 6 | 122 k | $1.55 M |